מכפיל P/S עתידי: Integra LifeSciences Holdings Corporation (IART)

With premium pricing power in neurosurgery, Integra LifeSciences (IART) has temporarily faced regulatory constraints. The projected P/S multiple, where the metric level is 0.00, helps assess the chances of a price recovery. Stable cash flow is supported by consistent demand for consumables, while growth potential is based on the restart of capacities and strategic acquisitions.

When screening for issuer reliability, it is critical to evaluate market value relative to expected sales. Forward P/S is calculated as the ratio of current market capitalization to projected revenue, eliminating the volatility of short-term quotes. For Integra LifeSciences (IART), this ratio reflects the market rate for synergies derived from the acquisition of biomaterial developers and neurosurgery partnerships. The trend of the forward P/S indicator on the GURU.Markets platform allows for the differentiation of real business growth from speculative liquidity inflows.